Original Article

You have free access to this content

Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations

  1. Bengt A. J. Källén1,*,
  2. Petra Otterblad Olausson2

Article first published online: 10 JAN 2007

DOI: 10.1002/bdra.20327

Issue

Birth Defects Research Part A: Clinical and Molecular Teratology

Birth Defects Research Part A: Clinical and Molecular Teratology

Volume 79, Issue 4, pages 301–308, April 2007

Additional Information

How to Cite

Källén, B. A. J. and Otterblad Olausson, P. (2007), Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Research Part A: Clinical and Molecular Teratology, 79: 301–308. doi: 10.1002/bdra.20327

Author Information

  1. 1

    Tornblad Institute, University of Lund, Lund, Sweden

  2. 2

    National Board of Health and Welfare, Centre for Epidemiology, Stockholm, Sweden

*Tornblad Institute, Biskopsgatan 7, SE-223 62 Lund, Sweden

Publication History

  1. Issue published online: 5 APR 2007
  2. Article first published online: 10 JAN 2007
  3. Manuscript Accepted: 18 SEP 2006
  4. Manuscript Revised: 22 AUG 2006
  5. Manuscript Received: 15 MAY 2006

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (102K)

REFERENCES

  • AlwanS,ReefhuisJ,RasmussenS, et al.2005.Maternal use of selective serotonin re-uptake inhibitors and risk for birth defects (Abstract).Birth Defects Res A Clin Mol Teratol 73:291.
  • CedergrenMI,KällénBAJ.2003.Maternal obesity and infant heart defects.Obesity Res 11:1065–1071.
  • Diav-CitrinO,SchechtmanS,WeinbaumD, et al.2005.Paroxetine and fluoxetine in pregnancy: a multicenter, prospective, controlled study (Abstract).Reprod Toxicol 20:459.
  • EricsonA,KällénB,WiholmB-E.1999.Delivery outcome after the use of antidepressants in early pregnancy.Europ J Clin Pharmacol 55:503–508.
  • GhaziHA,SpielbergerC,KällénB.1991.Delivery outcome after infertility —a registry study.Fertil Steril 55:726–732.
  • GoldsteinDJ,CorbinLA,SundellKL.1997.Effects of first-trimester fluoxetine exposure on the newborn.Obstet Gynecol 89:713–718.
  • HallbergP,SjöblomV.2005.The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects.J Clin Psychopharm 25:59–73.
  • HedegaardP,HenriksenTB,SecherNJ, et al.1996.Do stressful life events affect duration of gestation and risk of preterm delivery?Epidemiology 7:339–345.
  • HinesRN,AdamsJ,BuckGM, et al.2004.NTP-CERHR Expert Panel report on reproductive and developmental toxicity of fluoxetine.Birth Defects Res B Dev Reprod Toxicol 71:193–280.
    Direct Link:
  • KällénB,Otterblad OlaussonP.2001.Monitoring of maternal drug use and infant congenital malformations. Does loratadine cause hypospadias?Int J Risk Safety Med 14:115–119.
  • KällénB,Otterblad OlaussonP.2003.Maternal drug use in early pregnancy and infant congenital heart defect.Reprod Toxicol 17:255–261.
  • KällénB,Otterblad OlaussonP.2006.Antidepressant drugs during pregnancy and infant congenital heart defect. Letter to the Editor.Reprod Toxicol 21:221–222.
  • KällénB,Robert-GnansiaE.2005.Maternal drug use, fertility problems, and infant craniostenosis.Cleft Palate Craniofac J 42:589–593.
  • KällénK.2002.Maternal smoking and congenital malformations.Fetal Maternal Med Rev 13:63–86.
  • OberlanderTF,WarburtonW,MisriS, et al.2006.Neonatal outcome after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data.Arch Gen Psychiatry 63:898–906.
  • WilliamsM,WooltortonE.2005.Paroxetine (Paxil) and congenital malformations.Canad Med Assoc J 173:1320–1321.
  • WogeliusP,NørgaardM,MunkEM, et al.2005.Maternal use of selective serotonin reuptake inhibitors and risk of adverse pregnancy outcome (Abstract).Pharmacoepidem Drug Safety 14:S72–S73.
View Full Article (HTML) Get PDF (102K)